Thymidine: Clinical Trials

6 trials of Thymidine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 active not recruiting, 1 recruiting. 6 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 26Completed 4, Active not recruiting 1, Recruiting 1
Phase 11Active not recruiting 1

Follow Thymidine: new trials by email Literature Review of Thymidine trials Research Report on Thymidine

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Deoxynucleosides Pyrimidines as Treatment for Mitochondrial Depletion Syndrome
deoxycytidine and deoxythymidine - Mitochondrial Diseases, Mitochondrial Encephalomyopathy
Phase 2RecruitingKenneth Myers, MD2002021-10-182026-10-19
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Irinotecan, Bevacizumab, Trifluridine and Tipiracil Hydrochloride - Advanced Colorectal Carcinoma, Metastatic Colon Adenocarcinoma
Phase 2CompletedRoswell Park Cancer Institute422019-12-272026-02-10
Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma
Trifluridine and Tipiracil Hydrochloride, Oxaliplatin - Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8
Phase 2CompletedRoswell Park Cancer Institute222019-12-202025-04-29
An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency
doxecitine and doxribtimine - Thymidine Kinase 2 Deficiency
Phase 2CompletedUCB BIOSCIENCES, Inc.472019-07-052026-09-08
Treatment of TK2 Deficiency With Thymidine and Deoxycytidine
Thymidine - Mitochondrial DNA Depletion Syndrome 2 Myopathic Type, Thymidine Kinase 2 Deficiency
Phase 1 / Phase 2Active not recruitingColumbia University232017-05-162026-01-28
Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity
ribose, thymidine, uridine - 5'-Nucleotidase Syndrome
Phase 2CompletedNational Center for Research Resources (NCRR)1995-03-012005-06-24

Conditions studied

Mitochondrial Diseases (2)  ·  5-Nucleotidase syndrome (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Metabolism, Inborn Errors (1)  ·  Mitochondrial Encephalomyopathies (1)  ·  Mitochondrial encephalopathy (1)  ·  Muscle Weakness (1)  ·  Muscular Atrophy (1)  ·  Rare Diseases (1)  ·  Rectal Neoplasms (1)

Sponsors

Roswell Park Cancer Institute (2)  ·  Columbia University (1)  ·  Kenneth Myers, MD (1)  ·  National Center for Research Resources (NCRR) (1)  ·  UCB BIOSCIENCES, Inc. (1)

Countries

United States (4)  ·  Canada (1)  ·  Israel (1)  ·  Spain (1)

Top investigators

Alice L. Yu (1)  ·  Christos Fountilas, MD (1)  ·  Christos Fountzilas, MD (1)  ·  Kenneth Alexis MD Myers, MD PhD FRCPC (1)  ·  Michio Hirano, MD (1)

Results publications

PMID 33246973, PMID 11182283, PMID 12013896, PMID 12508073, PMID 12771225, PMID 12826641, PMID 15090651, PMID 15684706, PMID 16621917, PMID 16971696, PMID 16971699, PMID 17080429, PMID 17353390, PMID 17483096, PMID 17486094, PMID 17549623, PMID 18238797, PMID 18467430, PMID 18546365, PMID 19103785, PMID 19125351, PMID 19138848, PMID 19192035, PMID 19667227, PMID 19766516, PMID 19889013, PMID 20301762, PMID 20301791, PMID 20329599, PMID 20444604, PMID 21483760, PMID 21774628, PMID 21855607, PMID 22084276, PMID 22176657, PMID 22608879, PMID 22711161, PMID 23168274, PMID 23169334, PMID 23230576, PMID 23385875, PMID 23714749, PMID 23817075, PMID 23932787, PMID 245993, PMID 24708634, PMID 24968719, PMID 24985751, PMID 25857492, PMID 26342080

NIH funding

2018 (1), 2023 (1)